Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles.

Delivery of multiple therapeutics has become a preferred method of treating cancer, albeit differences in the biodistribution and pharmacokinetic profiles of individual drugs pose challenges in effectively delivering synergistic drug combinations to and at the tumor site. Here, bicompartmental Janus nanoparticles comprised of domains are reported with distinct bulk properties that allow for independent drug loading and release. Programmable drug release can be triggered by a change in the pH value and depends upon the bulk properties of the polymers used in the respective compartments, rather than the molecular structures of the active agents.

Design strategies for engineering soluto-inertial suspension interactions.

Soluto-inertial (SI) suspension interactions allow colloidal particles to be driven large distances over sustained periods of time. These interactions involve soluto-inertial "beacons" that establish and maintain solute fluxes over long times by slowly absorbing or emitting solutes in response to changes in the surrounding solution. Suspended particles then migrate in response to solute fluxes via diffusiophoresis (DP).

Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate.

Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non-optimal drug ratios. A modular framework has been developed that selectively delivers drug combinations at synergistic ratios via tumor-targeting aptamers for effective low-dose treatment.

Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation.

Combination chemotherapy is commonly used to treat late stage cancer; however, treatment is often limited by systemic toxicity. Optimizing drug ratio and schedule can improve drug combination activity and reduce dose to lower toxicity. Here, we identify gemcitabine (GEM) and doxorubicin (DOX) as a synergistic drug pair in vitro for the triple negative breast cancer cell line MDA-MB-231.

A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.

Combination chemotherapy is commonly used to treat advanced breast cancer. However, treatment success is often limited due to systemic toxicity. To improve therapeutic efficacy, polymer drug conjugates carrying synergistic pairs of chemotherapy drugs can be used to reduce drug administration dose.

DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its cardiotoxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to free doxorubicin. Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin And 5-Flurouracil Optimally Delivered In a Liposome) that inarguably offers superior therapeutic efficacies compared to free drug administrations. Delivery of synergistic ratios of this drug pair led to greater than 90% reduction in tumor growth of murine 4T1 mammary carcinoma in vivo.

Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.

Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clinical studies of these types of combinations have not progressed beyond phase II trials. The results of clinical combinations of topoisomerase (top) I and II inhibitors typically fall within one of two categories: little to no improvement in therapeutic efficacy, or augmented toxicity compared to the single drug counterparts. Hence, despite the promising activity of top I and II inhibitor combinations in vitro, their clinical applicability has not been realized.

Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting.

The impact of physical and chemical modifications of nanoparticles on their biological function has been systemically investigated and exploited to improve their circulation and targeting. However, the impact of nanoparticles' flexibility (i.e.

Measuring concentration fields in microfluidic channels in situ with a Fabry-Perot interferometer.

Recent advancements in microfluidic technology have allowed for the generation and control of complex chemical gradients; however, few general techniques can measure these spatio-temporal concentration profiles without fluorescent labeling. Here we describe a Fabry-Perot interferometric technique, capable of measuring concentration profiles in situ, without any chemical label, by tracking Fringes of Equal Chromatic Order (FECO). The technique has a sensitivity of 10(-5) RIU, which can be used to track local solute changes of ~0.

Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries.

Targeted delivery of therapeutic and imaging agents in the vascular compartment represents a significant hurdle in using nanomedicine for treating hemorrhage, thrombosis, and atherosclerosis. While several types of nanoparticles have been developed to meet this goal, their utility is limited by poor circulation, limited margination, and minimal targeting. Platelets have an innate ability to marginate to the vascular wall and specifically interact with vascular injury sites.

Using bulk convection in a microtensiometer to approach kinetic-limited surfactant dynamics at fluid-fluid interfaces.

The impact of transport of surfactants to fluid-fluid interfaces is complex to assess and model, as many processes are in the regime where kinetics, diffusion and convection are comparable. Using the principle that the timescale for diffusion decreases with increasing curvature, we previously developed a microtensiometer to accurately measure fundamental transport coefficients via dynamic surface tension at spherical microscale liquid-fluid interfaces. In the present study, we use a low Reynolds number flow in the bulk solution to further increase the rate of diffusion.